Inverse Agonist

A ligand that binds a receptor with constitutive activity and selectively stabilizes its inactive conformation, driving output below the unliganded baseline — occupying the negative end of a signed efficacy axis, distinct from an antagonist that merely blocks.

Core Idea

An inverse agonist is a ligand that binds a receptor possessing constitutive activity — a nonzero baseline signal produced without any agonist — and selectively stabilizes the inactive conformation, driving output below that baseline. It requires three features in series: a bistable receptor at equilibrium, a measurable spontaneous baseline, and a ligand with higher affinity for the inactive conformer. This is structurally distinct from antagonism, which occupies the receptor without altering the constitutive equilibrium.

Scope of Application

The inverse agonist lives within receptor pharmacology, reaching into engineered synthetic-biology regulators; its reach is bounded by a single precondition — a bistable receiver with constitutive activity plus a conformer-selective binder.

• Constitutively active GPCRs — the home turf: histamine H1 (cetirizine) and H2 (cimetidine), cannabinoid CB1.
• Reclassification of legacy "antagonists" — splitting blockers into tone-neutral versus basal-suppressing.
• Nuclear-receptor pharmacology — receptors displaying constitutive activity a negative ligand can suppress.
• Withdrawal / rebound analysis — anticipating rebound after chronic suppression of a baseline.
• Synthetic biology — engineered regulators deliberately given constitutive activity and negative ligands.

Clarity

Naming the inverse agonist dissolves a confusion baked into occupancy-only pharmacology: that a drug which blocks a receptor must leave the system where it found it. Two ligands an old assay would both file as "antagonists" can produce opposite basal effects. The sharper question becomes not "does it occupy the receptor?" but "does this ligand lower, leave, or raise the baseline tone?" — separating blocking an external signal from suppressing an internal one, and direction of effect from mode of binding.

Manages Complexity

Under occupancy-only accounts, a clinician would have to determine drug by drug whether a blocker leaves baseline alone, lowers it, or drives it negative — a thicket of paradoxical findings. The construct collapses that onto one signed scalar (intrinsic activity, negative through zero to positive) and one binary precondition (does the receptor have constitutive activity?). Fix the sign and the precondition, and the clinical consequences follow without per-drug re-derivation.

Abstract Reasoning

A diagnostic move infers direction-of-effect from conformational preference, reading a fall in basal output as the inverse-agonist signature. An interventionist move selects the ligand by the signed effect required and anticipates withdrawal rebound. A boundary-drawing move checks the constitutive-activity precondition and separates suppressing an internal signal from blocking an external one, and a predictive move reasons from the two-state equilibrium.

Knowledge Transfer

Within receptor pharmacology the category transfers as mechanism wherever its three-feature precondition is met — across constitutively active GPCRs and into nuclear receptors and engineered synthetic-biology regulators, because those reproduce the bistable-receiver-plus-conformer-selective-binder structure. Beyond systems that literally host a constitutive baseline the transfer is a more general mechanism: candidate "inverse agonists" collapse into the parent prime inhibition, shading into negative_feedback where a loop is involved. Those parents carry the lesson; the constitutive-baseline cargo stays home.

Relationships to Other Abstractions

Current abstraction Inverse Agonist Domain-specific

Parents (2) — more general patterns this builds on

• Inverse Agonist presupposes Efficacy Domain-specific

  Inverse Agonist presupposes Efficacy because it occupies the negative region of the same intrinsic-activity scale used for full and partial agonists.

• Inverse Agonist is a decomposition of Inhibition Prime

  Removing receptor vocabulary leaves an external agent that actively lowers an otherwise ongoing transformation rather than merely denying access.

Hierarchy paths (3) — routes to 3 parentless roots

• Inverse Agonist → Efficacy → Intrinsic Ceiling vs Input → Dose-Response Relationship → Function (Mapping)

Show alternative paths (2)

Neighborhood in Abstraction Space

Inverse Agonist sits in a sparse region of the domain-specific corpus (80^th percentile for distinctiveness): few abstractions share its structure, so a faithful description tends to retrieve it precisely.

Family — Pharmacokinetics & Drug Response (19 abstractions)

Nearest neighbors

• Partial Agonist — 0.85
• Efficacy — 0.85
• Neurotransmission — 0.83
• Pharmacodynamic Antagonism — 0.83
• Enzyme Inhibition — 0.82

Computed from structural-signature embeddings · 2026-07-12